Marshall Wace North America L.P. bought a new position in Gilead Sciences, Inc. (NASDAQ:GILD) in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 724,367 shares of the biopharmaceutical company’s stock, valued at approximately $51,430,000. Marshall Wace North America L.P. owned 0.06% of Gilead Sciences at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of GILD. Keel Point LLC lifted its holdings in shares of Gilead Sciences by 0.4% during the first quarter. Keel Point LLC now owns 3,111 shares of the biopharmaceutical company’s stock valued at $211,000 after acquiring an additional 11 shares during the period. West Oak Capital LLC lifted its holdings in shares of Gilead Sciences by 0.7% during the second quarter. West Oak Capital LLC now owns 4,666 shares of the biopharmaceutical company’s stock valued at $330,000 after acquiring an additional 32 shares during the period. First Heartland Consultants Inc. lifted its holdings in shares of Gilead Sciences by 0.4% during the second quarter. First Heartland Consultants Inc. now owns 8,927 shares of the biopharmaceutical company’s stock valued at $632,000 after acquiring an additional 39 shares during the period. Arrow Financial Corp lifted its holdings in shares of Gilead Sciences by 0.3% during the second quarter. Arrow Financial Corp now owns 17,771 shares of the biopharmaceutical company’s stock valued at $1,258,000 after acquiring an additional 45 shares during the period. Finally, Westover Capital Advisors LLC lifted its holdings in shares of Gilead Sciences by 0.8% during the first quarter. Westover Capital Advisors LLC now owns 5,563 shares of the biopharmaceutical company’s stock valued at $378,000 after acquiring an additional 46 shares during the period. 73.97% of the stock is owned by hedge funds and other institutional investors.

Shares of Gilead Sciences, Inc. (NASDAQ GILD) opened at 81.21 on Monday. Gilead Sciences, Inc. has a 1-year low of $63.76 and a 1-year high of $86.27. The firm has a 50-day moving average price of $82.63 and a 200 day moving average price of $72.65. The company has a market cap of $106.05 billion, a PE ratio of 8.82 and a beta of 1.14.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 EPS for the quarter, topping the consensus estimate of $2.11 by $0.45. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The business had revenue of $7.14 billion during the quarter, compared to analysts’ expectations of $6.35 billion. During the same quarter last year, the firm posted $3.08 earnings per share. The firm’s revenue was down 8.2% on a year-over-year basis. On average, equities analysts anticipate that Gilead Sciences, Inc. will post $8.74 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which was paid on Thursday, September 28th. Investors of record on Friday, September 15th were paid a dividend of $0.52 per share. The ex-dividend date was Thursday, September 14th. This represents a $2.08 annualized dividend and a yield of 2.56%. Gilead Sciences’s dividend payout ratio is currently 22.58%.

COPYRIGHT VIOLATION NOTICE: “Marshall Wace North America L.P. Takes $51.43 Million Position in Gilead Sciences, Inc. (GILD)” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another website, it was illegally copied and republished in violation of international trademark and copyright laws. The original version of this article can be read at https://www.thecerbatgem.com/2017/10/23/marshall-wace-north-america-l-p-takes-51-43-million-position-in-gilead-sciences-inc-gild.html.

In other Gilead Sciences news, insider John C. Martin sold 73,333 shares of the stock in a transaction that occurred on Tuesday, August 1st. The stock was sold at an average price of $75.86, for a total value of $5,563,041.38. Following the transaction, the insider now owns 3,199,969 shares in the company, valued at $242,749,648.34. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Gregg H. Alton sold 25,000 shares of the stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $82.65, for a total value of $2,066,250.00. The disclosure for this sale can be found here. Insiders have sold 446,819 shares of company stock valued at $36,338,919 in the last ninety days. 1.30% of the stock is currently owned by insiders.

GILD has been the subject of a number of analyst reports. Vetr raised Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $83.66 price objective for the company in a report on Monday, June 26th. Jefferies Group LLC reissued a “buy” rating and set a $82.00 price objective on shares of Gilead Sciences in a report on Tuesday, July 4th. J P Morgan Chase & Co reissued an “overweight” rating and set a $82.00 price objective on shares of Gilead Sciences in a report on Tuesday, July 4th. Cowen and Company reissued an “outperform” rating and set a $90.00 price objective on shares of Gilead Sciences in a report on Wednesday, July 5th. Finally, Morgan Stanley reissued an “equal weight” rating on shares of Gilead Sciences in a report on Tuesday, July 11th. One investment analyst has rated the stock with a sell rating, twelve have given a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $85.64.

Gilead Sciences Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.